Citations

Showing 10 of 108094 citations.

Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging
Feder, Nathanael Tigistu, Roberts, Rosebud O., Christianson, Teresa J., Petersen, Ronald C. , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Krell‐Roesch, Janina , Mielke, Michelle M. , Knopman, David S.

Mayo Clinic

Journal of Alzheimer's Disease | March 30, 2018 | Volume: 63 | Issue: 1 | Pages: 149-155

10.3233/jad-171141 | PMID 29614667 Get It

Adopted Individuals’ Views on the Utility and Value of Expanded Carrier Screening
Spencer, Sara , Ewing, Sarah, Calcagno, Kathryn, O’Neill, Suzanne C.

Mayo Clinic

Journal of Genetic Counseling | March 30, 2018 | Volume: 27 | Issue: 6 | Pages: 1341-1348

10.1007/s10897-018-0256-2 | PMID 29603037 Get It

AbstractAdoptees may not have family medical history and ethnicity information. Carrier screening assesses reproductive risk. Expanded carrier screening (ECS) screens for many genetic conditions regardless of a patient's knowledge of family history and ethnicity. This study aimed to better understand the opinions and attitudes of adopted individuals on the use of ECS in determining a patient's reproductive genetic risks. Specifically, the study assessed how adopted individuals feel that results of ECS may be useful to them and whether adoptees feel that meeting with a genetics professional in the process of undergoing ECS would be useful. Adult adoptees (N = 124) were recruited online. Their opinions on ECS were explored. The majority reported they had never been offered carrier screening (92%). The majority of adoptees wanted ECS (76%). Neither the amount of contact with biological relatives nor having medical knowledge about biological relatives was significantly associated with adoptees’ desire to pursue ECS. There was a significant positive correlation between adoptees of higher education levels and the amount they would pay for ECS (p = 0.004). The majority of participants (95%) indicated a genetics professional would be helpful when undergoing ECS. The findings suggest this population may want ECS and support from genetics healthcare professionals. Advocacy for genetic counseling and testing for adoptees appears justifiable.
Investigational drugs for vasospasm after subarachnoid hemorrhage
Tallarico, Roberta T. , Pizzi, Michael , Pizzi, Michael A , Freeman, William D.

Mayo Clinic

Expert Opinion on Investigational Drugs | March 30, 2018 | Volume: 27 | Issue: 4 | Pages: 313-324

10.1080/13543784.2018.1460353 | PMID 29600883 Get It

Clinical presentation of CIED infection following initial implant versus reoperation for generator change or lead addition
Harper, Mariko W. , Uslan, Daniel Z. , Greenspon, Arnold J. , Danik, Stephan B., Le, Katherine, Miró, José M., Naber, Christoph, Peacock, James E. , Vikram, Holenarasipur R. , Prutkin, Jordan M. , Vikram, Holenarasipur R. , Baddour, Larry M. , Carrillo, Roger G. , Tolosana, Jose María , Sohail, M. Rizwan

Mayo Clinic

Open Heart | March 30, 2018 | Volume: 5 | Issue: 1 | Pages: e000681

10.1136/openhrt-2017-000681 | PMID 29632673 Get It

Objective To explore differences in clinical manifestations and outcomes in those patients who develop infection after undergoing initial implantation versus reoperation. Methods We compared cases of cardiac implantable electronic device (CIED) infection based on initial implantation versus reoperation from 11 centres. Results There were 432 patients with CIED infection, 178 occurring after initial device placement and 254 after repeat reoperation. No differences were seen in age, sex or device type. Those with infection after initial implant had a higher Charlson Comorbidity Score (median 3 (IQR 2–6) vs 2 (IQR 1–4), p<0.001), shorter time since last procedure (median 8.9 months (IQR 0.9–33.3) vs 19.5 months (IQR 1.1–62.9), p<0.0001) and fewer leads (2.0±0.6vs 2.5±0.9, p<0.001). Pocket infections were more likely to occur after a reoperation (70.1%vs48.9%, p<0.001) and coagulase negative staphylococci (CoNS) was the most frequently isolated organism in this group (p=0.029). In contrast, initial implant infections were more likely to present with higher white cell count (10.5±5.1 g/dL vs 9.5±5.4 g/dL, p=0.025), metastatic foci of infection (16.9%vs8.7%, p=0.016) and sepsis (30.9%vs19.3%, p=0.006). There were no differences in in-hospital (7.9%vs5.2%, p=0.31) or 6-month mortality (21.9%vs14.0%, p=0.056). Conclusions CIED infections after initial device implant occur earlier, more aggressively, and often due to Staphylococcus aureus. In contrast, CIED infections after reoperation occur later, are due to CoNS, and have more indolent manifestations with primary localisation to the pocket.
Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease
Whitwell, Jennifer L. , Graff‐Radford, Jonathan, Tosakulwong, Nirubol , Weigand, Stephen D. , Senjem, Matthew L. , Spychalla, Anthony J., Vemuri, Prashanthi , Drubach, Daniel A., Ertekin‐Taner, Nilüfer , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Graff‐Radford, Jonathan , Machulda, Mary M. , Jones, David T. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | March 30, 2018 | Volume: 14 | Issue: 8 | Pages: 1005-1014

10.1016/j.jalz.2018.02.020 | PMID 29605222 Get It

Abstract Introduction Neuroimaging modalities can measure different aspects of the disease process in Alzheimer's disease, although the relationship between these modalities is unclear. Methods We assessed subject‐level regional correlations between tau on [ 18 F]AV‐1451 positron emission tomography (PET), β amyloid on Pittsburgh compound B PET, hypometabolism on [ 18 F] fluorodeoxyglucose PET, and cortical thickness on magnetic resonance imaging in 96 participants with typical and atypical Alzheimer's disease presentations. We also assessed how correlations between modalities varied according to age, presenting syndrome, tau‐PET severity, and asymmetry. Results [ 18 F]AV‐1451 uptake showed the strongest regional correlation with hypometabolism. Correlations between [ 18 F]AV‐1451 uptake and both hypometabolism and cortical thickness were stronger in participants with greater cortical tau severity. In addition, age, tau asymmetry, and clinical diagnosis influenced the strength of the correlation between [ 18 F]AV‐1451 uptake and cortical thickness. Discussion These findings support a close relationship between tau and hypometabolism in Alzheimer's disease but show that correlations between neuroimaging modalities vary across participants.
Olfactory function and neurocognitive outcomes in old age: The Atherosclerosis Risk in Communities Neurocognitive Study
Palta, Priya, Chen, Honglei , Sharrett, A. Richey, Gross, Alden L. , Griswold, Michael , Heiss, Gerardo , Deal, Jennifer A. , Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

Alzheimer's & Dementia | March 30, 2018 | Volume: 14 | Issue: 8 | Pages: 1015-1021

10.1016/j.jalz.2018.02.019 | PMID 29605223 Get It

AbstractIntroductionWe tested the hypothesis that poor sense of smell is associated with lower cognitive function and higher mild cognitive impairment (MCI) prevalence.MethodsOlfaction, measured by the Sniffin' Sticks test, was categorized as olfactory impairment (OI) (score ≤6) or no OI (score >6). MCI was adjudicated based on review of a neuropsychological examination. Linear regression estimated the mean difference in cognitive factor scores, and log‐binomial regression quantified MCI prevalence among participants with versus without OI.ResultsParticipants with OI had lower mean factor scores (memory: −0.27 standard deviation [SD], 95% confidence interval [CI]: −0.35 to −0.19; language: −0.24 SD, 95% CI: −0.30 to −0.17; executive function/processing speed: −0.09 SD, 95% CI: −0.12 to −0.06; and general cognitive performance: −0.25 SD, 95% CI: −0.30 to −0.20). OI was also associated with MCI (n = 204; prevalence ratio = 1.56, 95% CI: 1.37, 1.78).DiscussionAn impaired sense of smell may serve as a readily accessible early marker of neurodegeneration and improve upon the prevailing delayed diagnoses and underascertainment of MCI/dementia.
Developing drugs for treatment of atopic dermatitis in children (≥3 months to
Siegfried, Elaine C. , Jaworski, Jennifer C., Eichenfield, Lawrence F. , Altman, Emily , Arena, Charles, Block, Julie, Boguniewicz, Mark , Chen, Suephy C. , Hanna, Diane , Horii, Kimberly A., Hultsch, Thomas , Lio, Peter , Milner, Joshua D. , Omachi, Theodore A. , Schneider, Lynda C. , Sidbury, Robert , Smith, Timothy W. , Sugarman, Jeffrey, Taha, Sharif, Tofte, Susan, Tollefson, Megha M. , Tom, Wynnis L. , Whitney, Lucinda , Zane, Lee T., Tollefson, Megha, Paller, Amy S. , Hebert, Adelaide Ann , Simpson, Eric Lawrence , Blauvelt, Andrew , Cordoro, Kelly M. , Lee, James , Leung, Donald Y.M. , Schneider, Christine B. , Sugarman, Jeffrey, West, Dennis Paul

Mayo Clinic

Pediatric Dermatology | March 30, 2018 | Volume: 35 | Issue: 3 | Pages: 303-322

10.1111/pde.13452 | PMID 29600515 Get It

AbstractAtopic dermatitis is the most common chronic skin disease, and it primarily affects children. Although atopic dermatitis (AD) has the highest effect on burden of skin disease, no high‐level studies have defined optimal therapy for severe disease. Corticosteroids have been used to treat AD since the 1950s and remain the only systemic medication with Food and Drug Administration approval for this indication in children, despite published guidelines of care that recommend against this option. Several clinical trials with level 1 evidence have supported the use of topical treatments for mild to moderate atopic dermatitis in adults and children, but these trials have had little consistency in protocol design. Consensus recommendations will help standardize clinical development and trial design for children. The Food and Drug Administration issues guidance documents for industry as a source for “the Agency's current thinking on a particular subject.” Although they are nonbinding, industry considers these documents to be the standard for clinical development and trial design. Our consensus group is the first to specifically address clinical trial design in this population. We developed a draft guidance document for industry, Developing Drugs for Treatment of Atopic Dermatitis in Children (≥3 months to <18 years of age). This draft guidance has been submitted to the Food and Drug Administration based on a provision in the Federal Register (Good Guidance Practices).
Accuracy of probe-based confocal laser endomicroscopy (pCLE) compared to random biopsies during endoscopic surveillance of Barrett’s esophagus
Shah, Tilak , Lippman, Robert, Kohli, Divyanshoo R., Mutha, Pritesh , Solomon, Sanjeev , Zfass, Alvin M., Kohli, Divyanshoo

Mayo Clinic

Endoscopy International Open | March 29, 2018 | Volume: 06 | Issue: 04 | Pages: E414-E420

10.1055/s-0043-124868 | PMID 29607393 Get It

Abstract Background For surveillance of Barrett’s esophagus (BE), the current standard of random 4-quadrant biopsies misses 10 – 50 % of esophageal neoplasms, and does not permit real-time decision-making. Probe-based confocal laser endomicroscopy (pCLE) permits real-time in vivo histologic assessment of esophageal mucosa during upper endoscopy. Prospective studies comparing the accuracy of pCLE to 4-quadrant biopsies in routine clinical practice are lacking. Methods Consecutive patients with BE underwent high definition white light and narrow-band imaging followed by pCLE and targeted biopsy or mucosal resection. Four-quadrant biopsies were obtained during the same session. Baseline variables, real-time pCLE interpretation, and histology results were prospectively recorded. Blinded expert review of pCLE sequences and histology specimens was performed. A sample size of 64 patients was calculated a priori based on 3 % estimated prevalence of high grade dysplasia (HGD) or cancer. Results In total, 66 patients were included in the study. The prevalence of HGD or cancer was 4.55 %. Both real-time and blinded pCLE correctly identified all cases of cancer. For the primary outcome, real-time pCLE was 98 % specific but only 67 % sensitive for HGD/cancer compared to non-blinded pathologist interpretation. For HGD and cancer, inter-observer agreement was substantial between real-time and blinded endomicroscopists (kappa = 0.6). pCLE identified dysplasia in 75 % of cases where both blinded and unblinded pathology interpretation was low grade dysplasia. Conclusions pCLE demonstrates high specificity for detecting dysplasia and cancer, but lower sensitivity may limit its utility in routine BE surveillance. pCLE may have a role in confirming LGD in real-time before eradication therapy.
Patient with Marfan Syndrome and a Novel Variant in FBN1 Presenting with Bilateral Popliteal Artery Aneurysm
Helmi, Haytham , Atwal, Paldeep S. , Mohammad, Ahmed, Atwal, Paldeep S , Mohammad, Ahmed N.

Mayo Clinic

Case Reports in Genetics | March 29, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-4

10.1155/2018/6780494 | PMID 29796325 Get It

We present a 43-year-old man with aortic root dilation, mitral valve prolapse, and marfanoid appearance, who presented with acute onset left leg pain. He underwent a Doppler ultrasound that revealed left popliteal artery aneurysm with thrombus. CT angiogram showed bilateral popliteal artery aneurysms. After repairing of his left popliteal artery aneurysm, he was sent for genetic evaluation. He was diagnosed with Marfan syndrome (MFS) based on the revised Ghent criteria and then underwent FBN1 sequencing and deletion/duplication analysis, which detected a novel pathogenic variant in gene FBN1, denoted by c.5872 T>A (p.Cys1958Ser). MFS is a connective tissue disorder with an autosomal dominant inheritance due to pathogenic variants in FBN1 that encodes Fibrillin-1, a major element of the extracellular matrix, and connective tissue throughout the body. MFS involves multiple systems, most commonly the cardiovascular, musculoskeletal, and visual systems. In our case we present a rare finding of bilateral popliteal artery aneurysms in a male patient with MFS.
Vitamin D and the Breastfeeding Infant: Family Medicine Clinicians’ Knowledge, Attitudes, and Practices
Oberhelman, Sara S. , Cozine, Elizabeth W., Maxson, Julie, Thacher, Tom D. , Umaretiya, Puja J. , Maxson, Julie A, Thacher, Thomas D

Mayo Clinic

Journal of Human Lactation | March 29, 2018 | Volume: 34 | Issue: 2 | Pages: 331-336

10.1177/0890334418755338 | PMID 29596761 Get It

Background: The American Academy of Pediatrics and the National Academy of Medicine recommend vitamin D supplementation for breastfeeding infants. However, compliance with this recommendation is poor. Maternal supplementation with vitamin D is a safe and effective alternative to achieving vitamin D sufficiency in breastfeeding infants, and mothers have indicated a preference for self-supplementation over infant supplementation. Research aim: We sought to explore Family Medicine clinicians’ knowledge, attitudes, and practices regarding vitamin D supplementation recommendations for breastfeeding dyads. Methods: Fifty-six Family Medicine clinicians (including faculty physicians, resident physicians, and nurse practitioners/physician assistants) completed an online, anonymous survey regarding their knowledge and practices concerning vitamin D supplementation for breastfeeding infants. Results: The vast majority of clinicians (92.9%) correctly identified the American Academy of Pediatrics’ 2008 recommended dose for vitamin D supplementation in breastfeeding infants and estimated recommending vitamin D supplementation of exclusively breastfeeding infants 70.1% of the time. If all options were equivalent, clinicians would prefer to offer maternal or infant supplementation (50%) or maternal supplementation (37.5%) over infant supplementation (12.5%). Most (69.6%) preferred daily over monthly supplementation regimens. Conclusion: Family Medicine clinicians are knowledgeable regarding current recommendations for vitamin D supplementation in breastfeeding infants. They are also open to recommending maternal supplementation or offering parents a choice of maternal or infant vitamin supplementation.